Aptorum Group Ltd (APM)
: APM
· Real-Time Price · USD
n/a
n/a (n/a)
At close: Invalid Date
Aptorum Group Ltd (APM) Stock Price, Analysis & Data
No data available
| Bid | n/a |
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.36M |
| Beta | 0.17 |
| EPS (ttm) | n/a |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.99 |
| P/B (ttm) | 0.02 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | n/a |
| Volume | NaN |
| Avg. Volume (20D) | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a - n/a |
| 52-Week Range | n/a - n/a |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About APM
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the t...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 17, 2026
Employees 1
Stock Exchange NGM
Ticker Symbol APM
Website https://www.aptorumgroup.com
Financial Performance
In 2025, Aptorum Ltd's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -1.36M, a decrease of -68.06%.
Financial Statements
Page 1 of 2